Paul G. Richardson

TL;DR: The studies show that bortezomib is a substrate for Pgp but not the other drug efflux pumps, and suggests that in the subset of patients with advanced multiple myeloma or solid tumors which express high levels of Pgp, the efficacy of bortzomIB is synergistically enhanced by combinations with a Pgp inhibitor, while bortazomib treatment itself can reduce the expression of P gp.

TL;DR: Osteoclast biomarker serum CTX-1 correlates accurately with the disease burden in newly diagnosed multiple myeloma patients as compared to the rest of the groups and is a more sensitive early predictor of relapse/progressive disease than established biomarkers.

TL;DR: A review of the ubiquitin-proteasome system (UPS) and strategies for co-opting the UPS to reduce or eliminate proteins or survival factors key to malignant pathobiology, including multiple myeloma (MM) in particular, is provided in this article .

TL;DR: A deep whole genome sequencing on 260 MM samples was performed to comprehensively analyze recurrent somatic alterations in non-coding regions and showed that these frequent mutations have higher cancer cell fraction (CCF) [median CCF > 0.75] suggesting their occurrence earlier in the disease development.

TL;DR: The addition of daratumumab to RVd did not increase the incidence of VTEs, but the cumulative VTE incidence was relatively high in this cohort and anti‐thrombotic prophylaxis use was suboptimal.